drugset

drugset / Trial / NCT07828860

Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa

NCT07828860 ↗

Phase 1 Recruiting 25 enrolled Corvus Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

Safety and Efficacy of Soquelitinib in Adults with Hidradenitis Suppurativa

Timeline

Start: 2026-09-17
Primary completion: 2027-12
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Soquelitinib	Small molecule	—	Oral

Indications